Explore the upcoming biosimilar wave as major biologics like Keytruda and Eylea face patent expirations between 2025 and 2030. Learn about cost savings, safety, and market entry strategies.
Read Details
Evergreening lets drug companies extend patents on old medications through minor changes, blocking generics and keeping prices high. Learn how tactics like product hopping and patent thickets delay affordable alternatives-and what’s being done to stop it.
Read Details
